|
Evaluation of the prevalence of MET and protein tyrosine kinase 7 expression in non-small cell lung cancer to evaluate overlap of ADC antigens. |
| |
|
|
Stock and Other Ownership Interests - Abbvie |
| |
|
Honoraria - Abbvie; Amgen Astellas BioPharma; Anheart Therapeutics; Apollomics; AstraZeneca; BeiGene; BeiGene; bio-thera; Daiichi Sankyo; Dizal Pharma; Elevation Oncology; EMD Serono; Helsinn Therapeutics; Hengrui Pharmaceutical; Hummingbird; Janssen; Kestrel Labs; Lilly; Mersana; Mirati Therapeutics; nalo therapeutics; Nuvalent, Inc.; OnKure; Puma Biotechnology; Ribon Therapeutics; Roche; Sanofi; Seagen; takeda; Turning Point Therapeutics |
Research Funding - Inivata (Inst) |
| |
|
Honoraria - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Foundation One Inc; Gilead Sciences; GlaxoSmithKline; Janssen; Lilly O.; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; SERVIER; Takeda |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - Abbvie |
| |
|
|
Stock and Other Ownership Interests - Abbvie |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - Abbvie |
| |
|
|
Stock and Other Ownership Interests - Abbvie |
| |
|
|
Stock and Other Ownership Interests - AbbVie |
| |
|
|
Stock and Other Ownership Interests - Abbvie |
| |
|
|
|
Stock and Other Ownership Interests - Brogent; Fulgent Genetics |
Consulting or Advisory Role - Fulgent Genetics; Myriad Genetics |
Research Funding - Myriad Genetics (Inst) |
| |
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; GenomiCare; Hutchison MediPharma; InventisBio Co. Ltd; Menarini; Pfizer; Roche; Simcere; Yuhan; Zai Lab |
Speakers' Bureau - AstraZeneca; Hansoh Pharma; Hengrui Therapeutics; Roche |
Research Funding - AstraZeneca (Inst); BeiGene (Inst); BMS (Inst); Hansoh (Inst); Hengrui Therapeutics (Inst); Hutchison MediPharma (Inst); Lilly Suzhou Pharmaceutical Co. (Inst); Roche (Inst) |